Review Article | Published:

Modulation of autoimmune rheumatic diseases by oestrogen and progesterone

Nature Reviews Rheumatology volume 10, pages 740751 (2014) | Download Citation

Abstract

Sexual dimorphism is evident in the risk and expression of several human autoimmune diseases. Differences in disease manifestations observed between sexes are likely to involve immunomodulation by sex steroids, nonhormonal factors encoded by genes on the X and Y chromosomes, and immunological phenomena unique to pregnancy. In systemic lupus erythematosus (SLE), and perhaps other autoantibody-mediated diseases, oestrogen seems to increase the risk of disease in genetically predisposed women by targeting key immune pathways, including the type 1 interferon (IFN) response, differentiation of CD4+ T helper cells and survival of autoreactive B cells. By contrast, progesterone seems to reduce the risk of SLE by counteracting the effects of oestrogen on some of these same pathways, which suggests that the balance between oestrogen and progesterone can determine disease expression. In this Review we focus on the roles of the sex steroid hormones oestrogen and progesterone in modulating the risk and expression of SLE and rheumatoid arthritis. Intensive research in this area promises to identify novel therapeutic strategies and improve understanding of the immunological requirements and complications of pregnancy, and is expected to define the mechanisms behind sexual dimorphism in autoimmunity, immunity and other aspects of human health—a newly announced directive of the NIH.

Key points

  • Sexual dimorphism in the risk and expression of human autoimmune rheumatic diseases involves the immunomodulatory effects of postpubertal levels of sex steroid hormones

  • Oestrogen increases the risk of SLE in genetically susceptible women by increasing type 1 interferon production and favouring the survival of B cells that produce pathogenic IgG autoantibodies

  • Progesterone might reduce the risk of SLE in genetically predisposed women by countering these oestrogen effects—thus, the balance between oestrogen and progesterone might influence the risk of SLE

  • Pregnancy-induced amelioration of rheumatoid arthritis probably involves anti-inflammatory and tolerogenic effects of high circulating levels of progesterone, oestrogen and cortisol

  • Research into mechanisms of sex-steroid-related immunomodulation is expected to uncover novel therapeutic targets in autoimmune rheumatic conditions and to improve understanding of sexual dimorphism in risk of other diseases

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , & Sexual dimorphism in autoimmune disease. Curr. Mol. Med. 9, 1058–1079 (2009).

  2. 2.

    Sex differences in autoimmune disease. Nat. Immunol. 2, 777–780 (2001).

  3. 3.

    , & Evolutionary-developmental perspectives on immune system interactions among the pregnant woman, placenta, and fetus, and responses to sexually transmitted infectious agents. Ann. NY Acad. Sci. 1230, 25–47 (2011).

  4. 4.

    et al. Mammalian Y chromosomes retain widely expressed dosage-sensitive regulators. Nature 508, 494–499 (2014).

  5. 5.

    , & Sex hormones and the immune response in humans. Hum. Reprod. Update 4, 411–423 (2005).

  6. 6.

    , & The X chromosome in immune functions: when a chromosome makes the difference. Nat. Rev. Immunol. 10, 594–604 (2010).

  7. 7.

    , & Interaction of pregnancy and autoimmune rheumatic disease. Autoimmun. Rev. 11, A437–A446 (2012).

  8. 8.

    & Michrochimerism: an investigative frontier in autoimmunity and transplantation. JAMA 291, 1127–1131 (2009).

  9. 9.

    The influence of sex and gender on the immune response. Autoimmun. Rev. 11, A479–A485 (2012).

  10. 10.

    & NIH to balance sex in cell and animal studies. Nature 509, 282–283 (2014).

  11. 11.

    et al. Estrogen and progesterone receptors: from molecular structures to clinical targets. Cell. Mol. Life Sci. 66, 2405–2426 (2009).

  12. 12.

    & Estrogen receptors in immunity and autoimmunity. Clin. Rev. Allergy Immunol. 40, 66–73 (2011).

  13. 13.

    et al. Classification and pharmacology of progestins. Maturitas 61, 171–180 (2008).

  14. 14.

    Epidemiology of systemic lupus erythematosus. Best Pract. Res. Clin. Rheumatol. 16, 847–858 (2002).

  15. 15.

    & What can epidemiology tell us about systemic lupus erythematosus? Int. J. Clin. Pract. 61, 1170–1180 (2007).

  16. 16.

    , , & Late-onset systemic lupus erythematosus. Drugs Aging 29, 181–189 (2012).

  17. 17.

    & Age, sex, and race effects on mortality from systemic lupus erythematosus in the United States. Arthritis Rheum. 21, 473–479 (1978).

  18. 18.

    & Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat. Rev. Rheumatol. 6, 538–546 (2010).

  19. 19.

    et al. Distinctive clinical features of pediatric systemic lupus erythematosus in three different age classes. Lupus 16, 550–555 (2007).

  20. 20.

    et al. Puberty is associated with a marked increase of the female sex predominance in chronic autoimmune thyroiditis. Horm. Res. 72, 52–56 (2009).

  21. 21.

    , , & Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum. 56, 1251–1262 (2007).

  22. 22.

    et al. Menstrual and hormonal alterations in juvenile systemic lupus erythematosus. Lupus 18, 38–43 (2009).

  23. 23.

    , , & Ovarian function and disease activity in patients with systemic lupus erythematosus. Clin. Exp. Rheumatol 26, 436–441 (2008).

  24. 24.

    , , , & Reproductive factors and risk of systemic lupus erythematosus: nationwide cohort study in Denmark. J. Rheumatol. 36, 1903–1909 (2009).

  25. 25.

    , , & Combined oral contraceptive use and the risk of systemic lupus erythematosus. Arthritis Rheum. 61, 476–481 (2009).

  26. 26.

    , , , & BALES: the Baltimore lupus environmental study [abstract]. Arthritis Rheum. 44, S331 (2001).

  27. 27.

    et al. Combined oral contraceptives in women with systemic lupus erythematosus. N. Engl. J. Med. 353, 2550–2558 (2005).

  28. 28.

    et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N. Engl. J. Med. 353, 2539–2549 (2005).

  29. 29.

    et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann. Intern. Med. 142, 953–962 (2005).

  30. 30.

    et al. Pregnane progestin contraception in systemic lupus erythematosus: a longitudinal study of 187 patients. Contraception 83, 229–237 (2011).

  31. 31.

    et al. Tibolone in postmenopausal women with systemic lupus erythematosus: a pilot study. Maturitas 62, 311–316 (2008).

  32. 32.

    Immunology and the menstrual cycle. Autoimmun. Rev. 11, A486–A492 (2012).

  33. 33.

    et al. Hormones, immune response, and pregnancy in healthy women and SLE patients. Swiss Med. Wkly 140, 187–201 (2010).

  34. 34.

    & Evaluation and management of systemic lupus erythematosus and rheumatoid arthritis during pregnancy. Clin. Immunol. 149, 225–235 (2013).

  35. 35.

    et al. Pregnancy, cytokines, and disease activity in systemic lupus erythematosus. Arthritis Rheum. 51, 989–995 (2004).

  36. 36.

    , , & Sex hormone modulation of autoimmunity in NZB/W mice. Arthritis Rheum. 22, 1162–1169 (1979).

  37. 37.

    et al. Decrease in glomerulonephritis and Th1-associated autoantibody production after progesterone treatment in NZB/NZW mice. Arthritis Rheum. 60, 1775–1784 (2009).

  38. 38.

    , , , & Effect of castration and sex hormone treatment on survival, anti-nucleic acid antibodies, and glomerulonephritis in NZB/NZW F1 mice. J. Exp. Med. 147, 1568–1583 (1978).

  39. 39.

    et al. Estrogen receptor-alpha deficiency attenuates autoimmune disease in (NZB × NZW)F1 mice. Genes Immun. 9, 137–152 (2008).

  40. 40.

    & Effects of estrogen receptor subtype-selective agonists on autoimmune disease in lupus-prone NZB/NZW F1 mouse model. Clin. Immunol. 123, 219–226 (2007).

  41. 41.

    , , & Oestrogen is a potent disease accelerator in SLE-prone lpr/lpr mice. Clin. Exp. Immunol. 80, 467–473 (1990).

  42. 42.

    , , , & Impact of estrogen receptor deficiency on disease expression in the NZM2410 lupus prone mouse. Clin. Immunol. 128, 259–268 (2008).

  43. 43.

    , , & The effects of nandrolone, testosterone and their decanoate esters on murine lupus. Clin. Exp. Immunol. 44, 11–17 (1981).

  44. 44.

    , & Androgenic hormones modulate autoantibody responses and improve survival in murine lupus. J. Clin. Invest. 59, 1066–1070 (1977).

  45. 45.

    , & Effects of prolonged adminstration of the 19-nor-testosterone derivatives norethindrone and norgestrel to female NZB/W mice: comparison with medroxyprogesterone and ehtinyl estradiol. Autoimmunity 9, 21–32 (1991).

  46. 46.

    et al. Depomedroxyprogesterone-induced hypoestrogenism and changes in vaginal flora and epithelium. Obstet. Gynecol. 96, 431–439 (2000).

  47. 47.

    & The epidemiology of autoimmune diseases. Autoimmun. Rev. 2, 119–125 (2003).

  48. 48.

    , , , The national database of the German Collaborative Arthritis Centres: I. Structure, aims, and patients. Ann. Rheum. Dis. 60, 199–206 (2001).

  49. 49.

    , , & Do breast-feeding and other reproductive factors influence future risk of rheumatoid arthritis? Results from the Nurses' Health Study. Arthritis Rheum. 50, 3458–3467 (2004).

  50. 50.

    et al. Effects of postmenopausal hormone therapy on rheumatoid arthritis: the women's health initiative randomized controlled trials. Arthritis Rheum. 59, 302–310 (2008).

  51. 51.

    , & Sexual disparities in the incidence and course of SLE and RA. Clin. Immunol. 149, 211–218 (2013).

  52. 52.

    & Sexual dimorphism of RA manifestations: genes, hormones and behavior. Nat. Rev. Rheumatol. 7, 307–310 (2011).

  53. 53.

    , , , & Does pregnancy provide vaccine-like protection against rheumatoid arthritis? Arthritis Rheum. 7, 1842–1848 (2010).

  54. 54.

    Mechanisms of T cell tolerance towards the allogeneic fetus. Nat. Rev. Immunol. 13, 23–33 (2013).

  55. 55.

    & Pregnancy and pregnancy-associated hormones alter immune responses and disease pathogenesis. Horm. Behav. 62, 263–271 (2012).

  56. 56.

    , & Female sex hormones ameliorate arthritis in SKG mice. Biochem. Biophys. Res. Commun. 434, 740–745 (2013).

  57. 57.

    et al. Ethinyl estradiol treats collagen-induced arthritis in DBA/1LacJ mice by inhibiting the production of TNF-alpha and IL-1beta. Clin. Immunol. 115, 162–72 (2005).

  58. 58.

    & Type 1 interferons: crucial participants in disease amplification in autoimmunity. Nat. Rev. Rheumatol. 6, 40–49 (2010).

  59. 59.

    & Interferons in autoimmune and inflammatory diseases: regulation and roles. J. Interferon Cytokine Res. 31, 857–865 (2011).

  60. 60.

    , , & Type 1 interferons (α/β) in immunity and autoimmunity. Ann. Rev. Immunol. 23, 307–336 (2005).

  61. 61.

    & Type I interferon and systemic lupus erythematosus. J. Interferon Cytokine Res. 31, 803–812 (2011).

  62. 62.

    Interferon-inducible Ifi200-family genes as modifiers of lupus susceptibility. Immunol. Lett. 147, 10–17 (2012).

  63. 63.

    & Cytokines as therapeutic targets in SLE. Nat. Rev. Rheumatol. 6, 339–347 (2010).

  64. 64.

    , & The Xs and Y of immune responses to viral vaccines. Lancet Infect. Dis. 10, 338–349 (2010).

  65. 65.

    et al. Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat. Med. 15, 955–959 (2009).

  66. 66.

    et al. TLR7 ligands induce higher IFN-alpha production in females. J. Immunol. 177, 2088–2096 (2006).

  67. 67.

    et al. The TLR-mediated response of plasmacytoid dendritic cells is positively regulated by estradiol in vivo through cell-intrinsic estrogen receptor signaling. Blood 119, 454–464 (2012).

  68. 68.

    , & Expression of murine Unc93b1 is up-regulated by interferon and estrogen signaling: implications for sex bias in the development of autoimmunity. Int. Immunol. 25, 521–529 (2013).

  69. 69.

    et al. Gender-dependent expression of murine Irf5 gene: implications for sex bias in autoimmunity. J. Mol. Cell Biol. 2, 284–290 (2010).

  70. 70.

    , , , & Mutually positive regulatory feedback loop between interferons and estrogen receptor-alpha in mice: implications for sex bias in autoimmunity. PLoS ONE 5, e10868 (2010).

  71. 71.

    et al. Sex-specific assoctiation of X-linked toll-like receptor 7 (TLR7) with male systemic lupus erythematosus. Proc. Natl Acad. Sci. USA 107, 15838–15843 (2010).

  72. 72.

    et al. Analysis of autosomal genes reveals gene-sex interactions and higher total genetic risk in men with systemic lupus erythematosus. Ann. Rheum. Dis. 71, 694–699 (2012).

  73. 73.

    et al. Osteopontin and systemic lupus erythematosus association: a probable gene-gender interaction. PLoS ONE 3, e0001757 (2008).

  74. 74.

    , , , & Progesterone regulates IFN-alpha production by plasmacytoid dendritic cells. J. Immunol. 180, 2029–2033 (2008).

  75. 75.

    et al. Hormonal contraception and HIV-1 infection: medroxyprogesterone acetate suppresses innate and adaptive immune mechanisms. Endocrinology 154, 1282–1295 (2013).

  76. 76.

    et al. Progesterone suppresses interferon signaling by repressing TLR-7 and MxA expression in peripheral blood mononuclear cells of patients infected with hepatitis C virus. Arch. Virol. 158, 1755–1764 (2013).

  77. 77.

    , , , & Interferon-related and other immune genes are downregulated in periphral blood leukocytes in the luteal phase of the mentrual cycle. J. Clin. Endocrinol. Metab. 89, 2501–2504 (2004).

  78. 78.

    et al. Gender bias in autoimmunity is influenced by microbiota. Immunity 39, 400–412 (2013).

  79. 79.

    et al. Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. Science 339, 1084–1088 (2013).

  80. 80.

    et al. Double-stranded RNA of intestinal commensal but not pathogenic bacteria triggers production of protective interferon-beta. Immunity 38, 1187–1197 (2013).

  81. 81.

    et al. Interferon-epsilon protects the female reproductive tract from viral and bacterial infection. Science 339, 1088–1092 (2013).

  82. 82.

    , , & X chromosome regulation: diverse patterns in development, tissues and disease. Nat. Rev. Genet. 15, 367–378 (2014).

  83. 83.

    et al. Early B-lymphocyte precursors and their regulation by sex steroids. Immunol. Rev. 175, 128–137 (2000).

  84. 84.

    , & Estrogen up-regulates Bcl-2 and blocks tolerance induction of naive B cells. Proc. Natl Acad. Sci. USA 97, 2703–2708 (2000).

  85. 85.

    , , , & Differential roles of estrogen receptors alpha and beta in control of B-cell maturation and selection. Mol. Med. 17, 211–220 (2011).

  86. 86.

    , & Identification of candidate genes that influence sex hormone-dependent disease phenotypes in mouse lupus. Genes Immun. 9, 47–56 (2008).

  87. 87.

    , , , & Estrogen alters thresholds for B cell apoptosis and activation. J. Clin. Invest. 109, 1625–1633 (2002).

  88. 88.

    & Murine BAFF expression is up-regulated by estrogen and interferons: implications for sex bias in the development of autoimmunity. Mol. Immunol. 53, 15–23 (2013).

  89. 89.

    The role of activation-induced deaminase in lupus nephritis. Autoimmunity 46, 115–120 (2013).

  90. 90.

    et al. Abrogation of lupus nephritis in activation-induce deaminase-deficient MRL/lpr mice. J. Immunol. 178, 7422–7431 (2007).

  91. 91.

    & Changes in immunoglobulin class and subclass of anti-DNA antibodies with increasing age in N/ZBW F1 hybrid mice. Clin. Exp. Immunol. 26, 363–370 (1976).

  92. 92.

    , , , & Estrogen directly activates AID transcription and function. J. Exp. Med. 206, 99–111 (2009).

  93. 93.

    & Progesterone inhibits activation-induced deaminase by binding to the promoter. J. Immunol. 183, 1238–1244 (2009).

  94. 94.

    , , , & Serial studies of the IgG subclass and functional affinity of DNA antibodies in systemic lupus erythematosus. J. Autoimmun. 1, 483–494 (1988).

  95. 95.

    , & Differential characteristics of immune-bound antibodies in diffuse proliferative and membranous forms of lupus glomerulonephritis. Clin. Immunol. Immunopathol. 29, 223–241 (1983).

  96. 96.

    , , & Molecular and cellular basis for pathogenecity of autoantibodies: lessons from murine monoclonal autoantibodies. Springer Semin. Immunopathol. 28, 175–184 (2006).

  97. 97.

    & Structure and function of immunoglobulins. J. Allergy Clin. Immunol. 125, S41–S52 (2010).

  98. 98.

    Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr. Opin. Immunol. 20, 471–478 (2008).

  99. 99.

    , , , & The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu. Rev. Immunol. 25, 21–50 (2007).

  100. 100.

    et al. Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study. Arthritis Res. Ther. 11, R193 (2009).

  101. 101.

    et al. Association between galactosylation of immunoglobulin G. and improvement of rheumatoid arthritis during pregnancy is independent of sialylation. J. Proteome Res. 12, 4522–4531 (2013).

  102. 102.

    et al. Human IgG Fc-glycosylation profiling reveals associations with age, sex, female sex hormones and thyroid cancer. J. Proteomics 75, 2824–2834 (2012).

  103. 103.

    et al. Estrogen receptor alpha is necessary in thymic development and estradiol-induced thymic alterations. J. Immunol. 163, 4168–4174 (1999).

  104. 104.

    , , , & Progesterone receptors in the thymus are required for thymic involution during pregnancy and for normal fertility. Proc. Natl Acad. Sci. USA 96, 12021–12026 (1999).

  105. 105.

    , & Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 38, 13–25 (2013).

  106. 106.

    , , & Estrogen upregulates cyclic AMP response element modulator alpha expression and downregulates interleukin-2 production by human T lymphocytes. Mol. Med. 18, 370–378 (2012).

  107. 107.

    , , , & Gender differences in autoimmune diseases: estrogen increases calcineurin expression in systemic lupus erythematosus. Clin. Immunol. Immunopathol. 89, 171–180 (1998).

  108. 108.

    et al. Estradiol enhances primary antigen-specific CD4 T cell responses and Th1 development in vivo. Essential role of estrogen receptor alpha expression in hematopoietic cells. Eur. J. Immunol. 33, 512–521 (2003).

  109. 109.

    , & The intracellular progesterone receptor regulates CD4+ T cells and T cell-dependent antibody responses. J. Leukoc. Biol. 93, 369–375 (2013).

  110. 110.

    , , , & Progesterone promotes differentiation of human cord blood fetal T cells into T regulatory cells but suppresses their differentiation into Th17 cells. J. Immunol. 187, 1778–1787 (2011).

  111. 111.

    , & Development and maintenance of regulatory T cells. Immunity 38, 414–423 (2013).

  112. 112.

    et al. Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat. Med. 20, 62–68 (2014).

  113. 113.

    , , & Regulatory T cells protect from autoimmune arthritis during pregnancy. J. Autoimmun. 38, J103–J108 (2012).

  114. 114.

    et al. Estrogen drives expansion of the CD4+CD25+ regulatory T cell compartment. J. Immunol. 173, 2227–2230 (2004).

  115. 115.

    et al. Progesterone increases systemic and local uterine proportions of CD4+CD25+ Treg cells during midterm pregnancy in mice. Endocrinology 151, 5477–5488 (2010).

  116. 116.

    , & Progesterone suppresses the mTOR pathway and promotes generation of induced regulatory T cells with increased stability. Eur. J. Immunol. 42, 1–14 (2012).

  117. 117.

    , , & Pregnancy imprints regulatory memory that sustains anergy to fetal antigen. Nature 490, 102–106 (2012).

  118. 118.

    & Regulation of dendritic cells by female sex steroids: relevance to immunity and autoimmunity. Autoimmunity 40, 470–481 (2007).

  119. 119.

    et al. Estradiol promotes functional responses in inflammatory and steady-state dendritic cells through differential requirement for activation function-1 of estrogen receptor alpha. J. Immunol. 190, 5459–5470 (2013).

  120. 120.

    et al. Estriol generates tolerogenic dendritic cells in vivo that protect against autoimmunity. J. Immunol. 186, 3346–3355 (2011).

  121. 121.

    et al. Differential modulation of TLR3- and TLR4-mediated dendritic cell maturation and function by progesterone. J. Immunol. 185, 4525–4534 (2010).

  122. 122.

    et al. Disruption of maternal immune balance maintained by innate DC subsets results in spontaneous pregnancy loss in mice. Immunobiology 217, 951–961 (2012).

  123. 123.

    , & Cells of the synovium in rheumatoid arthritis. Macrophages. Arthritis Res. Ther. 9, 224 (2007).

  124. 124.

    & Regulation of TNF-alpha production in activated mouse macrophages by progesterone. J. Immunol. 160, 5098–5104 (1998).

  125. 125.

    , , , & Progesterone inhibits inducible nitric oxide synthase gene expression and nitric oxide production in murine macrophages. J. Leukoc. Biol. 59, 442–450 (1996).

  126. 126.

    , , & Selective inhibition and augmentation of alternative macrophage activation by progesterone. Immunology 134, 281–291 (2011).

  127. 127.

    et al. Toll-like receptor-4-mediated macrophage activation is differentially regulated by progesterone via the glucocorticoid and progesterone receptors. Immunology 125, 59–69 (2008).

  128. 128.

    , , & Effects of testosterone, estrogen and progesterone on TNF-alpha mediated cellular damage in rat arthritic synovial fibroblasts. Rheumatol. Int. 32, 3181–3188 (2012).

  129. 129.

    et al. 17Beta-estradiol promotes TLR4-triggered proinflammatory mediator production through direct estrogen receptor alpha signaling in macrophages in vivo. J. Immunol. 185, 1169–1176 (2010).

  130. 130.

    , & Estrogen regulates the IFN-gamma promoter. J. Immunol. 146, 4362–4367 (1991).

  131. 131.

    , , & Gender-dependent IL-12 secretion by APC is regulated by IL-10. J. Immunol. 164, 6237–6243 (2000).

Download references

Acknowledgements

The authors thank J. L. Nelson, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA and M. Wener, University of Washington, Seattle, WA, USA for their thoughtful comments during the writing of this Review. Research work in G.H.'s laboratory has been supported by NIH grant AI101564 and the Robert F. and Betty Snead Fund for Innovation in Lupus Research. Research work in D.C.'s laboratory has been supported by grants AI066261 and AI089775 from the NIH and a Veterans Administration Merit Award (5 I01 BX001133).

Author information

Affiliations

  1. Division of Rheumatology, Department of Medicine, University of Washington, 1959 NE Pacific Street, Box 356428, Seattle, WA 98195, USA.

    • Grant C. Hughes
  2. Cincinnati Veterans Administration Medical Center, 3200 Vine Street, Cincinnati, OH 45220, USA.

    • Divaker Choubey

Authors

  1. Search for Grant C. Hughes in:

  2. Search for Divaker Choubey in:

Contributions

Both authors contributed equally to researching data for the article, providing a substantial contribution to discussions of the content, writing the article, and to the review and/or editing of the manuscript before submission.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Grant C. Hughes.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrrheum.2014.144

Further reading